GAS6 expression identifies high-risk adult AML patients: Potential implications for therapy

Leukemia

Volumn 28, Issue 6, 2014, Pages 1252-1258

  Whitman, S P ^a   Kohlschmidt, J ^a,b   Maharry, K ^a,b   Volinia, S ^c   Mrozek K ^a   Nicolet, D ^a,b   Schwind, S ^a   Becker, H ^a   Metzeler, K H ^a   Mendler, J H ^a   Eisfeld, A K ^a   Carroll, A J ^d   Powell, B L ^e   Carter, T H ^f   Baer, M R ^g   Kolitz, J E ^h   Park, I K ^a   Stone, R M ⁱ   Caligiuri, M A ^a   Marcucci, G ^a   Bloomfield, C D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h NORTH SHORE UNIVERSITY HOSPITAL   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; GAS6; prognosis

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; INTERLEUKIN 8; POLO LIKE KINASE; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BAALC GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DEATH; DISEASE FREE SURVIVAL; DNA REPLICATION; FEMALE; GAS6 GENE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEPATOMEGALY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MERTK GENE; MN1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; STROMA CELL; THROMBOCYTE COUNT; TYRO3 GENE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, CXCR; RECEPTORS, CXCR4; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84902086753     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.371     Document Type: Article

References (62)

1. Masson K, Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009; 21: 1717-1726.
2. Correll PH, Paulson RF, Wei X. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Gene 2006; 374: 26-38. (Pubitemid 43737116)
3. Zheng R, Klang K, Gorin NC, Small D. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk Res 2004; 28: 121-126. (Pubitemid 37487991)
4. Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 2009; 4: 77-82.
5. Sritana N, Auewarakul CU. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups. Exp Mol Pathol 2008; 85: 227-231.
6. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19: 1361-1366. (Pubitemid 41136329)
7. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study. J Clin Oncol 2006; 24: 3904-3911. (Pubitemid 46630738)
8. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295.
9. Hafizi S, Dahlba?ck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295-304. (Pubitemid 44038616)
10. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011; 10: 1763-1773.
11. Brandaö L, Migdall-Wilson J, Eisenman K, Graham DK. TAM receptors in leukemia: Expression, signaling, and therapeutic implications. Crit Rev Oncog 2011; 16: 47-63.
12. Suarez RM, Chevot F, Cavagnino A, Saettel N, Radvanyi F, Piguel S et al. Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation. Eur J Med Chem 2013; 61: 2-25.
13. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010; 29: 5254-5264.
14. Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 2013; 32: 5359-5368.
15. Crosier PS, Hall LR, Vitas MR, Lewis PM, Crosier KE. Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk Lymphoma 1995; 18: 443-449.
16. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999; 13: 1352-1358. (Pubitemid 29429761)
17. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-4985. (Pubitemid 23220402)
18. Dirks W, Rome D, Ringel F, Ja?ger K, MacLeod RA, Drexler HG. Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk Res 1999; 23: 643-651. (Pubitemid 29243869)
19. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903. (Pubitemid 24299870)
20. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671-1677.
21. Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. J Clin Oncol 1999; 17: 2831-2839. (Pubitemid 29415241)
22. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol 2008; 26: 4934-4939.
23. Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B study 9720. Leukemia 2011; 25: 800-807.
24. Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz JE et al. A phase III randomized trial of intensive induction and consolidation chemotherapy±oblimersen, a proapoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients 460 years old [abstract]. J Clin Oncol 2007; 25: 360 (abstract 7012).
25. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010; 116: 1413-1421.
26. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 2008; 33: 239-244.
27. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD et al. Absence of the wild-Type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-7239. (Pubitemid 32946520)
28. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008; 111: 1552-1559.
29. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418-1425.
30. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C et al. Long-Term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 2007; 109: 5164-5167.
31. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-And microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 596-604.
32. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 5078-5087.
33. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 4595-4602.
34. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373-1381.
35. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348-2355.
36. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 2012; 30: 3109-3118.
37. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920-6929.
38. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K et al. Age related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30: 742-750.
39. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 2010; 116: 5660-5669.
40. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-Associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2009; 27: 3198-3204.
41. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
42. Ferrari F, Bortoluzzi S, Coppe A, Sirota A, Safran M, Shmoish M et al. Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics 2007; 8: 446.
43. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
44. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Springer: New York, NY, USA, 2003.
45. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
46. Cox DR. Regression models and life-Tables. J R Stat Soc Series B (Methodological) 1972; 34: 187-220.
47. Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol 2013; 34: 629-636.
48. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615-625.
49. Alachkar H, Maharry K, Santhanam R, Neviani P, Volinia S, Kohlschmidt J et al. SPARC contributes to leukemia growth and aggressive disease in acute myeloid leukemia (AML). Blood 2012; 120: (abstract 773).
50. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 2013; 31: 923-929.
51. Ahn JY, Seo K, Weinberg OK, Arber DA. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol 2013; 21: 79-84.
52. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007; 109: 1152-1156. (Pubitemid 46435395)
53. Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: Implications for Axl as a potential therapeutic target. Blood 2013; 121: 2064-2073.
54. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-Talk of leukemia cells with bone marrow stroma. Blood 2013; 122: 2443-2452.
55. Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D et al. Meta-Analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int 2013; 2013: 238284.
56. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 130-138. (Pubitemid 351377987)
57. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1124-1136. (Pubitemid 350235020)
58. Schmidt T, Ben-Batalla I, Schultze A, Loges S. Macrophage-Tumor crosstalk: Role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci 2012; 69: 1391-1414.
59. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 2010; 70: 7570-7579.
60. Hattermann K, Mentlein R. An infernal trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Ann Anat 2013; 195: 103-110.
61. Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT et al. Safety and efficacy of upfront plerixafor+G-CSF vs placebo+G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients X60 and o60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Am J Hematol 2013; 88: 1017-1023.
62. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924.